Back to top
more

Acer Therapeutics (ACER)

(Delayed Data from OTC)

$0.66 USD

0.66
NA

0.00 (0.00%)

Updated Nov 20, 2023 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (154 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Acer's (ACER) NDA for ACER-001 in UCD Gets FDA Acceptance

by Zacks Equity Research

The FDA accepts Acer's (ACER) NDA for ACER-001 (sodium phenylbutyrate) for the treatment of patients with urea cycle disorders. A decision is due on Jun 5, 2022. Stock up.

Opexa Therapeutics, Inc. (ACER) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Opexa Therapeutics, Inc. (ACER) delivered earnings and revenue surprises of 36.11% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Savara (SVRA) Initiates Dosing in Pivotal Lung Disorder Study

by Zacks Equity Research

Savara (SVRA) is developing its lead pipeline candidate, molgramostim, as a potential treatment for autoimmune pulmonary alveolar proteinosis.

Jazz Pharma (JAZZ) Gets FDA Approval for Leukemia Drug Rylaze

by Zacks Equity Research

Jazz Pharma (JAZZ) gets FDA approval for Rylaze to treat acute lymphoblastic leukemia or lymphoblastic lymphoma with hypersensitivity to asparaginase.

Zacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer Therapeutics

by Zacks Equity Research

Zacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer Therapeutics

Kinjel Shah headshot

4 Small Drug Stocks Set to Escape the COVID-Led Industry Weakness

by Kinjel Shah

Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry in the second quarter of 2021. However, with demand trends expected to improve, XNCR, ORGO, CPIX, and ACER may prove to be good additions to one's portfolio.

What Makes Opexa Therapeutics, Inc. (ACER) a New Buy Stock

by Zacks Equity Research

Opexa Therapeutics, Inc. (ACER) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

New Strong Sell Stocks for September 3rd

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Factors Setting the Tone for Deere (DE) in Q3 Earnings

by Zacks Equity Research

Replacement demand for agricultural equipment and strong demand in construction likely to be conducive to Deere's (DE) third-quarter fiscal 2019 results.

Can Pharmacy Services Drive CVS Health's (CVS) Q2 Earnings?

by Zacks Equity Research

Akin to the previous quarters, net new business and the steady uptake of Maintenance Choice programs are likely to bolster CVS Health's (CVS) PBM business in Q2.

Is a Beat in Store for Axon Enterprise's (AAXN) Q2 Earnings?

by Zacks Equity Research

Axon Enterprise's (AAXN) expanded product offerings and strong execution likely to drive Q2 performance.

Tenet Healthcare (THC) Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Tenet Healthcare's (THC) second-quarter earnings are likely to suffer due to lower revenues.

Acer Shares Down on FDA's CRL for Genetic Disorder Treatment

by Zacks Equity Research

Acer Therapeutics Inc. (ACER) receives a Complete Response Letter from the FDA regarding its new drug application for Edsivo for the treatment of vascular Ehlers-Danlos syndrome.

Opexa Therapeutics Enters Oversold Territory

by Zacks Equity Research

Opexa Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Top Ranked Momentum Stocks to Buy for November 23rd

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 23rd:

Opexa Therapeutics Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Opexa Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

    Acer Therapeutics (ACER) Shares March Higher, Can It Continue?

    by Zacks Equity Research

    Investors certainly have to be happy with Acer Therapeutics Inc. (ACER) and its short term performance

      Kinjel Shah headshot

      Small Drugmakers Edging Out the Bigshots: 7 Stocks to Buy

      by Kinjel Shah

      Smaller drugmakers are having a relatively better year than their larger counterparts. Here are seven stocks to buy.

        Why Opexa Therapeutics (ACER) Could Shock the Market Soon

        by Zacks Equity Research

        Although overlooked by the investors, Opexa Therapeutics (ACER) looks well-positioned for a solid gain, supported by a favorable Zacks rank and positive estimate revisions.

          Top Ranked Momentum Stocks to Buy for May 18th

          by Zacks Equity Research

          Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, May 18th:

            Will Segmental Revenues Aid Cooper's (COO) Q1 Earnings?

            by Zacks Equity Research

            CooperSurgical sales and broad product spectrum are key catalysts for Cooper's (COO) Q1 earnings. However, falling estimates of other segments are likely to mar prospects.